1.

Record Nr.

UNINA9910831047903321

Titolo

From genome to therapy : integrating new technologies with drug development

Pubbl/distr/stampa

[Place of publication not identified], : John Wiley, 2000

ISBN

1-280-55549-1

9786610555499

0-470-85183-X

0-470-84664-X

Edizione

[1st ed.]

Descrizione fisica

1 online resource (173 pages)

Collana

Novartis Foundation symposium  From genome to therapy

Disciplina

615/.19

Soggetti

Pharmacogenomics

Pharmacogenetics

Pharmacology

Computational Biology

Drug Discovery

Genetics

Investigative Techniques

Biology

Biological Science Disciplines

Health Occupations

Chemistry, Pharmaceutical

Natural Science Disciplines

Disciplines and Occupations

Chemistry

Analytical, Diagnostic and Therapeutic Techniques and Equipment

Drug Design

Genomics

Health & Biological Sciences

Pharmacy, Therapeutics, & Pharmacology

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Note generali

Bibliographic Level Mode of Issuance: Monograph



Sommario/riassunto

This important and exciting work brings together a high-calibre group of experts to discuss the practical application of genomic information to the development of drugs. Recent technological advances have led to a rapid acceleration in our ability to gather genetic data. The complete genetic sequences are now known for several organisms and accelerated programmes are in place for sequencing many other genomes, including human. The speed with which complete sequencing can be accomplished will continue to increase as new technologies come online. In principle, the scope for developing new diagnostic techniques and drugs is now greater than at any time in human history, but the pathway from genetic information to usable drug is a long and complex one.This major book covers such subjects as the current state of the art in squencing technology, the applications of these new technologies to sequencing the genomes of various organisms, and the challenge of proteomics. Additional contributions deal with legal and ethical implications of the new uses of genetic data, and functional genomics from the point of view of the pharmaceutical industry.